Buzzberg Cup Live

Spintronics: The Tiny Chips Solving The Humanoid Hand

Asymmetrical Bets · Asymmetrical Bets · July 09, 2026 at 19:52 · ⏱ 7 min read  | Read on Substack ↗
Summary
The article argues that spintronics, specifically NVE Corp's magnetic sensors, are the key enabling technology for humanoid robot hand dexterity, and that NVE is a high-margin, US-based manufacturer already integrated into humanoid hands and pacemakers, making it a compelling but overlooked investment opportunity.
  • NVE Corp (NVEC) is a 35-year-old Minnesota chipmaker with a $500M market cap, $5M quarterly net income, 60% net margins, no debt, $20M cash, and 93% institutional ownership.
  • Spintronics uses electron spin instead of charge, enabling ultra-low-power, high-precision magnetic sensors small enough for fingertip integration.
  • Management confirmed NVE's parts are inside humanoid hands being developed by an unnamed customer, and the company doubled its operational capacity last quarter.
  • Precedence Research forecasts the spintronics market growing at 36.48% CAGR from $2.2B (2026) to $49.33B (2035), with NVE listed as a 'Major Player' by Mordor Intelligence.
  • Abbott (via Pacesetter) likely accounts for 37% of NVE's revenue through a long-term pacemaker supplier deal, providing a sticky, high-margin revenue floor.
  • NVE's in-house US fabrication of spintronic films is a competitive moat as supply chains shift toward domestic suppliers.
Read time 7 min
Length 7,707 chars
Category finance
Ideas
Asymmetrical Bets Substack author, Asymmetrical Bets
The article presents a strong bullish thesis on NVE as a pure-play spintronics company with confirmed humanoid robot hand integration, high margins, and a recently expanded fab capacity — but no perso
The article presents a strong bullish thesis on NVE as a pure-play spintronics company with confirmed humanoid robot hand integration, high margins, and a recently expanded fab capacity — but no personal position or explicit recommendation is disclosed by the author. Risk: Customer concentration (Abbott ~37% of revenue and a single humanoid customer) poses revenue risk; the humanoid market is nascent and unproven at scale.
More from Asymmetrical Bets

This newsletter, published July 09, 2026, features Asymmetrical Bets discussing NVEC. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: Asymmetrical Bets  · Tickers: NVEC